Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 11/20 | 0.74 |
| ▸ | HTR2A | P28223 | 11/20 | 0.74 |
| ▸ | DRD2 | P14416 | 8/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.74 |
| ▸ | HTR7 | P34969 | 3/20 | 0.74 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.74 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.74 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.74 |
| ▸ | HTR6 | P50406 | 2/20 | 0.74 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.74 |
| ▸ | HTR3B | O95264 | 1/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.74 |
| ▸ | PGR | P06401 | 1/20 | 0.74 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.74 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.74 |
| ▸ | MAPT | P10636 | 1/20 | 0.74 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.74 |
| ▸ | GOT1 | P17174 | 1/20 | 0.74 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7099059 | 0.99 | KCNH2 (0.73) | HTR1AHTR2ADRD2KCNH2HTR7 | |
| Water SCHEMBL7416199 | 0.93 | KCNH2 (0.67) | HTR1AHTR2ADRD2KCNH2HTR7 | |
| SCHEMBL9367026 | 0.91 | HTR2A (0.69) | HTR1AHTR2ADRD2KCNH2HTR7 | |
| Hydrochloric Acid SCHEMBL9367191 | 0.90 | HTR2A (0.67) | HTR1AHTR2ADRD2KCNH2HTR7 | |
| SCHEMBL9366288 | 0.90 | HTR1A (0.62) | HTR1AHTR2ADRD2KCNH2HTR7 | |
| Hydrochloric Acid SCHEMBL9367186 | 0.90 | HTR2A (0.67) | HTR1AHTR2ADRD2KCNH2HTR7 | |
| SCHEMBL13285208 | 0.85 | HTR2A (0.80) | HTR1AHTR2ADRD2KCNH2HTR7 | |
| SCHEMBL9367637 | 0.85 | HTR1A (0.60) | HTR1AHTR2ADRD2KCNH2HTR7 | |
| SCHEMBL7942300 | 0.85 | HTR2A (0.93) | HTR1AHTR2ADRD2KCNH2HTR7 | |
| Ziprasidone SCHEMBL4774002 | 0.85 | HTR2A (1.00) | HTR1AHTR2ADRD2KCNH2HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20080269246-A1 | METHOD FOR TREATING PEDIATRIC BIPOLAR DISORDER | PFIZER INC | 2008-10-30 | — | — | US | disclosed |
| EP-1757292-A1 | Method of treating ocd and tic disorders | Pfizer Products Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-0901789-B1 | Method of treating tourette's syndrome | PFIZER PROD INC (US) | 2007-01-03 | — | — | EP | disclosed |
| EP-1633361-A1 | ANXIETY TREATMENTS WITH ZIPRASIDONE | Pfizer Products Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1633360-A1 | TREATMENT OF PSYCHOTIC AND DEPRESSIVE DISORDERS | Pfizer Products Incorporated (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1626722-A1 | METHOD FOR ENHANCING COGNITION USING ZIPRASIDONE | Pfizer Products Inc. (US) | 2006-02-22 | — | — | EP | disclosed |
| EP-1626723-A1 | TREATMENT OF BIPOLAR DISORDERS AND ASSOCIATED SYMPTOMS | Pfizer Products Inc. (US) | 2006-02-22 | — | — | EP | disclosed |
| US-20050038036-A1 | Stabilization patient; antidepressant; psychological disorders; mood cycles | PFIZER INC | 2005-02-17 | — | — | US | disclosed |
| US-20020004504-A1 | METHOD OF TREATING GLAUCOMA AND ISCHEMIC RETINOPATHY | HOWARD HARRY R (US) | 2002-01-10 | — | — | US | disclosed |
| US-6245766-B1 | USING A PIPERAZINE COMPOUND | PFIZER INC | 2001-06-12 | — | — | US | disclosed |
| US-6127373-A | Method of treating tourette's syndrome and obsessive compulsive disorder | PFIZER INC. (US) | 2000-10-03 | — | — | US | disclosed |
| EP-0985414-A2 | Method of treating glaucoma and ischemic retinopathy | Pfizer Products Inc. (US) | 2000-03-15 | — | — | EP | disclosed |
| EP-0931547-A1 | Piperazinyl-heterocyclic compounds in the treatment of psychiatric conditions | Pfizer Products Inc. (US) | 1999-07-28 | — | — | EP | disclosed |
| EP-0901789-A1 | Method of treating tourette's syndrome | Pfizer Products Inc. (US) | 1999-03-17 | — | — | EP | disclosed |
| EP-0281309-B1 | PIPERAZINYL-HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 1991-12-27 | — | — | EP | disclosed |
| US-4883795-A | Piperazinyl-heterocyclic compounds | PFIZER INC. (US) | 1989-11-28 | — | — | US | disclosed |
| US-4831031-A | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity | PFIZER INC. (US) | 1989-05-16 | — | — | US | disclosed |
| EP-0281309-A1 | Piperazinyl-heterocyclic compounds | PFIZER INC. (US) | 1988-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038036-A1 | Stabilization patient; antidepressant; psychological disorders; mood cycles | MC2R, NR3C1, CRH | HTR1A 79/4885HTR2A 295/4885DRD2 199/4885 |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | HTR6, GAP43, HTR5A | HTR1A 7/4885HTR2A 5/4885DRD2 242/4885 |
| US-20020004504-A1 | METHOD OF TREATING GLAUCOMA AND ISCHEMIC RETINOPATHY | ALDH1A2, NDUFB7, PTGS1 | HTR1A 1024/4885HTR2A 2202/4885DRD2 3644/4885 |
| US-20080269246-A1 | METHOD FOR TREATING PEDIATRIC BIPOLAR DISORDER | GABBR1, GABRR1, GABBR2 | HTR1A 80/4885HTR2A 179/4885DRD2 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.